The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET PRE-OPEN: UK inflation races; GSK in decent booster data

Wed, 15th Dec 2021 07:44

(Alliance News) - Stock prices in London are seen opening lower on Wednesday, as traders digest news that the UK's inflation raced above 5% for the first time in over 10 years.

It means pressure is mounting on the Bank of England, which holds a key monetary policy meeting on Thursday.

"Unfortunately for consumers, peak inflation may still be a few months off. Today's CPI data only serves to increase the pressure on the Bank of England to raise interest rates at its MPC meeting tomorrow," Quilter Cheviot analyst Richard Carter commented.

IG futures indicate the FTSE 100 index is to open 15.7 points, 0.2%, lower at 7,204.14. The blue-chip index closed down 12.80 points, 0.2%, at 7,202.94 on Tuesday.

The pound was quoted at USD1.3248 early Wednesday following the CPI data, up from USD1.3231 at the London equities close on Tuesday.

The euro stood at USD1.1269, soft on USD1.1275. Against the yen, the dollar was trading at JPY113.70, unchanged from the London equities close on Tuesday.

In early UK corporate news, meanwhile, distribution firm Bunzl said it expects single-digit annual revenue growth, GlaxoSmithKline shared promising data from its Covid-19 booster and electrical goods firm Currys warned its market has been "softer" in recent weeks.

Inflation in the UK raced above 5% in November, numbers on Wednesday showed, ahead of a crunch Bank of England meeting on Thursday.

The UK's annual inflation rate accelerated to 5.1% in November, from 4.2% in October, according to the Office for National Statistics. The Bank of England's inflation target is 2%.

November's figure was above market estimates of 4.7%, according to FXStreet.

"This is the highest CPI 12-month inflation rate since September 2011, when it stood at 5.2%," the ONS said.

"Inflation may stay around 5.0% for about six months and may even nudge up a bit further in April 2022. But we still think it will start to fall sharply from June 2022, perhaps to quite close to 2.0% by the end of 2022. So while the Bank of England won't be able to ignore the inflation backdrop for long (we wouldn't completely rule out a hike tomorrow), we doubt it will raise interest rates next year as far as the 1.00% level priced into the markets," analysts at Capital Economics commented.

Producer price growth, meanwhile, similarly topped estimates in November, surging 9.1% yearly, versus expectations of an 8.3% hike. October's growth was upwardly revised to 8.6%.

On the London Stock Exchange, Bunzl said it expects to post a "strong performance in 2021". Underlying revenue growth will be in the "high single digit" level compared to 2019, before the onset of the pandemic.

Revenue in 2021 is tipped to rise 2% year-on-year at actual exchange rates, and 7% on a constant currency basis.

"At constant exchange rates, underlying revenue growth is expected to reflect a strong recovery in the base business, supported by inflation, partially offset by the anticipated decline in Covid-19 related orders with deflation on certain Covid-19 related products. Group adjusted operating margin is expected to be only slightly ahead of historical levels," the company said.

Bunzl noted uncertainty related to new Covid-19 variants, but added that it expects revenue to increase in 2022. However, it warned sales of Covid-19 related products could moderate.

"Continued recovery of the base business is expected to be offset by the further normalisation of sales of Covid-19 related products, albeit these are expected to remain ahead of 2019 levels. Similarly, we expect the continued normalisation of group operating margins in 2022 to more historical levels, as the mix of sector and product sales returns to more typical levels for the group," the company explained.

GlaxoSmithKline, developing a Covid-19 jab alongside French firm Sanofi, said a single booster dose of the vaccine delivered "consistently strong immune responses".

Neutralising antibodies increased in the 9- to 43-fold range, GSK said, regardless of which initial jab the patient took, be it AstraZeneca's, J&J's, Moderna or Pfizer's.

"The booster was well tolerated, with a safety profile similar to currently approved Covid-19 vaccines. This is the most comprehensive booster trial to date to explore boosting across different vaccine technologies used for primary vaccination," GSK added.

The companies plan to file the booster data with regulators following full phase III results.

Among mid-caps, Currys said it has seen "strong UK market share gains", despite supply chain challenges.

In the half year to October 30, revenue fell 1.5% annually to GBP4.79 billion from GBP4.86 billion. Pretax profit, however, inched up 6.7% to GBP48 million from GBP45 million, helped by net finance costs dropping 15% to GBP47 million.

"We've had a strong first half of the year. We grew colleague engagement and customer satisfaction, gained market share and stabilised gross margins in the UK, grew profits and generated strong cash flow," Chief Executive Alex Baldock said.

The company, which announced plans for a GBP75 million buyback in November, said the programme will begin in January.

Currys declared an interim payout of 1.00 pence per share, having not paid one a year earlier.

An increased dividend, along with a return of surplus cash and a pledge to invest in the business, are among its "refreshed capital allocation priorities".

Looking ahead, CEO Baldock added: "Our market has been softer over recent weeks, and we may face into further headwinds from omicron and associated restrictions, but the stronger business we've built can ride out both the industry-wide disruption to supply chains and bumpy demand. After the strong first half, we remain on track to meet the expectations we set out a month ago for full year adjusted pretax profit of around GBP160 million."

Tokyo's Nikkei 225 inched up 0.1%. The Shanghai Composite ended down 0.4%, while the Hang Seng in Hong Kong was 0.9% lower in late trade. The S&P/ASX 200 in Sydney fell 0.7%.

Gold stood at USD1,767.83 an ounce early Wednesday, down from USD1,775.45 late Tuesday. Brent oil was quoted at USD72.89 a barrel, down from USD73.23.

Still to come on Wednesday are US retail sales numbers at 1330 GMT.

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
2 May 2024 19:57

GSK knew about Zantac cancer risk, attorneys tell jury in first trial

May 2 (Reuters) - U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued heartburn drug Zantac on Thursday told a jury in Chicago that pharmaceutical companies GSK and Boehringer Ingelheim knew the product could cause cancer if it was not handled properly but failed to warn the public.

Read more
2 May 2024 09:48

LONDON BROKER RATINGS: Deutsche Bank likes TP ICAP but says sell CMC

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and Wednesday:

Read more
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.